Q3 Earnings Forecast for CalciMedica Issued By HC Wainwright

CalciMedica Inc. (NASDAQ:CALC) – Equities researchers at HC Wainwright dropped their Q3 2025 earnings per share estimates for CalciMedica in a report released on Tuesday, August 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.40) for the quarter, down from their prior estimate of ($0.39). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.66) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($0.68) EPS.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.40).

CalciMedica Stock Up 11.5%

Shares of NASDAQ CALC opened at $2.91 on Friday. The company has a market capitalization of $40.65 million, a price-to-earnings ratio of -1.82 and a beta of 1.33. The company has a debt-to-equity ratio of 1.39, a current ratio of 5.45 and a quick ratio of 5.66. The business has a 50-day moving average of $2.36 and a two-hundred day moving average of $2.12. CalciMedica has a 1 year low of $1.42 and a 1 year high of $5.97.

Institutional Trading of CalciMedica

Institutional investors have recently bought and sold shares of the business. First Manhattan CO. LLC. purchased a new stake in CalciMedica during the 1st quarter worth about $25,000. 180 Wealth Advisors LLC purchased a new stake in CalciMedica during the 1st quarter worth about $31,000. Cetera Investment Advisers lifted its holdings in CalciMedica by 37.1% during the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after buying an additional 4,566 shares during the last quarter. Sound View Wealth Advisors Group LLC purchased a new stake in CalciMedica during the 2nd quarter worth about $32,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in CalciMedica during the 1st quarter worth about $45,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.